Harbour BioMed announces $225 million Series A to advance porustobart
Harbour BioMed says it has announced a $225 million Series A financing with partner Solstice Oncology to advance porustobart, a neoadjuvant immuno-oncology therapy.
, ROTTERDAM, Netherlands and SHANGHAI, Sept. 9, 2026 // -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced tha…